Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated:  1/29/2016
Columbia University Medical Center
mi
from
New York, NY
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated: 1/29/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated:  1/29/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated: 1/29/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated:  1/29/2016
Nationwide Children's Hospital
mi
from
Columbus, OH
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated: 1/29/2016
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated:  1/29/2016
Oregon Health and Science University
mi
from
Portland, OR
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated: 1/29/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated:  1/29/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated: 1/29/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated:  1/29/2016
Cook Children's Medical Center
mi
from
Fort Worth, TX
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated: 1/29/2016
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated:  1/29/2016
Hospital for Sick Children
mi
from
Toronto,
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated: 1/29/2016
Hospital for Sick Children
mi
from
Toronto,
Click here to add this to my saved trials
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas
Status: Enrolling
Updated:  1/29/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas
Status: Enrolling
Updated: 1/29/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  2/1/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 2/1/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
University of Alabama at Birbingham School of Medicine
mi
from
South Birmingham, AL
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
University of Alabama at Birbingham School of Medicine
mi
from
South Birmingham, AL
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Arizona Cancer Center
mi
from
Tucson, AZ
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Rush University Medical Center
mi
from
Chicago, IL
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Northwestern Memorial Hospital
mi
from
Chicago, IL
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Jewish Hospital Medical Center
mi
from
Louisville, KY
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Jewish Hospital Medical Center
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Massachusetts General Hospital
mi
from
Boston, MA
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
The New Jersey Neuroscience Institute
mi
from
Edison, NJ
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
The New Jersey Neuroscience Institute
mi
from
Edison, NJ
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
The Long Island Brain Tumor Center at Neurological Surgery, PC
mi
from
Great Neck, NY
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
The Long Island Brain Tumor Center at Neurological Surgery, PC
mi
from
Great Neck, NY
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
NYU Clinical Cancer Center
mi
from
New York, NY
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
NYU Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Cleveland Clinic Rose Ella Burkhardt Brain Tumor and Neuro Oncology Center
mi
from
Cleveland, OH
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Cleveland Clinic Rose Ella Burkhardt Brain Tumor and Neuro Oncology Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Sammons Cancer Center (Baylor)
mi
from
Dallas, TX
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Sammons Cancer Center (Baylor)
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
University of Texas Health Science Center at Houston
mi
from
Houston, TX
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
University of Virginia Health System
mi
from
Charlottesville, VA
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Massachusetss General Hospital
mi
from
Boston, MA
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Massachusetss General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Weil Cornell Medical College
mi
from
New York, NY
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Weil Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Wake Forest University
mi
from
Winston Salem, NC
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Wake Forest University
mi
from
Winston Salem, NC
Click here to add this to my saved trials
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated:  2/2/2016
Penn State Hershey Medical Center
mi
from
Hershey, PA
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status: Enrolling
Updated: 2/2/2016
Penn State Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma
A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma
Status: Enrolling
Updated:  2/3/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma
A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma
Status: Enrolling
Updated: 2/3/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research
Collection of Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research
Status: Enrolling
Updated:  2/3/2016
Children's Memorial Hospital
mi
from
Chicago, IL
Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research
Collection of Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research
Status: Enrolling
Updated: 2/3/2016
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Acupuncture for the Treatment of Cancer Related Fatigue
A Phase II Study of Acupuncture for the Treatment of Cancer Related Fatigue in Children and Adolescents With Central Nervous System Tumors
Status: Enrolling
Updated:  2/3/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Acupuncture for the Treatment of Cancer Related Fatigue
A Phase II Study of Acupuncture for the Treatment of Cancer Related Fatigue in Children and Adolescents With Central Nervous System Tumors
Status: Enrolling
Updated: 2/3/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
MicroRNAs in Patients With Neurofibromatosis Type 1
MicroRNAs as Disease Markers for Central Nervous System Tumors in Patients With Neurofibromatosis Type 1
Status: Enrolling
Updated:  2/3/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
MicroRNAs in Patients With Neurofibromatosis Type 1
MicroRNAs as Disease Markers for Central Nervous System Tumors in Patients With Neurofibromatosis Type 1
Status: Enrolling
Updated: 2/3/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Status: Enrolling
Updated:  2/4/2016
Rady Children's Hospital
mi
from
San Diego, CA
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Status: Enrolling
Updated: 2/4/2016
Rady Children's Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Status: Enrolling
Updated:  2/4/2016
Cardinal Glennon Children's Medical Center
mi
from
St. Louis, MO
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Status: Enrolling
Updated: 2/4/2016
Cardinal Glennon Children's Medical Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Status: Enrolling
Updated:  2/4/2016
Levine Children's Hospital
mi
from
Charlotte, NC
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Status: Enrolling
Updated: 2/4/2016
Levine Children's Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Status: Enrolling
Updated:  2/4/2016
Medical University of South Carolina
mi
from
Charleston, SC
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Status: Enrolling
Updated: 2/4/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Status: Enrolling
Updated:  2/4/2016
Arnold Palmer Hospital for Children- MD Anderson
mi
from
Orlando, FL
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Status: Enrolling
Updated: 2/4/2016
Arnold Palmer Hospital for Children- MD Anderson
mi
from
Orlando, FL
Click here to add this to my saved trials
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Status: Enrolling
Updated:  2/4/2016
Uvm/Fahc
mi
from
Burlington, VT
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Status: Enrolling
Updated: 2/4/2016
Uvm/Fahc
mi
from
Burlington, VT
Click here to add this to my saved trials
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  2/4/2016
Children's Healthcare of Atlanta Childern Hosp - ATL
mi
from
Atlanta, GA
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 2/4/2016
Children's Healthcare of Atlanta Childern Hosp - ATL
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  2/4/2016
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. John Hopkins
mi
from
Baltimore, MD
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 2/4/2016
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. John Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  2/4/2016
Dana Farber Cancer Institute DFCI (3)
mi
from
Boston, MA
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 2/4/2016
Dana Farber Cancer Institute DFCI (3)
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  2/4/2016
Seattle Children's Hospital CPKC412A2114
mi
from
Seattle, WA
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 2/4/2016
Seattle Children's Hospital CPKC412A2114
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  2/4/2016
Novartis Investigative Site
mi
from
Parkville,
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 2/4/2016
Novartis Investigative Site
mi
from
Parkville,
Click here to add this to my saved trials
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
A Phase I/II, Dual-Center, Open-Label Trial of the Safety and Efficacy of Tarceva™ (Erlotinib Hydrochloride) Plus Sirolimus in Patients With Recurrent Malignant Glioma Not on P450-Inducing Anti-Epileptics
Status: Enrolling
Updated:  2/5/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
A Phase I/II, Dual-Center, Open-Label Trial of the Safety and Efficacy of Tarceva™ (Erlotinib Hydrochloride) Plus Sirolimus in Patients With Recurrent Malignant Glioma Not on P450-Inducing Anti-Epileptics
Status: Enrolling
Updated: 2/5/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials